Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine [human papillomavirus vaccine recombinant quadrivalent] in Solid Organ Transplant Recipients.

Trial Profile

Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine [human papillomavirus vaccine recombinant quadrivalent] in Solid Organ Transplant Recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Genital warts; Human papillomavirus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Aug 2012 Planned end date changed from 1 Mar 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 06 Sep 2011 Planned End Date changed from 1 Dec 2010 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 30 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top